Mallinckrodt (MNK) PT Lowered to $87 at Mizuho Ahead of Q3 Print
- Wall Street rises, buoyed by economic data; Dow sets high
- Twitter (TWTR) 'Takeover Money' Moves On as 'Trump Money' Moves In
- Amazon (AMZN) Could Open Over 2,000 Brick-and Mortar Groceries if Tests Succeed - DJ; Kroger (KR) on Watch
- Buy Any Seasonal Market Weakness Ahead of Year End Rally - Oppenheimer (SPY)
- After-Hours Stock Movers 12/05: (TXMD) (COUP) (BOBE) Higher; (SB) (LXRX) (STWD) Lower (more...)
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Mizuho Securities analyst Irina Koffler lowered her price target on Buy-rated Mallinckrodt plc (NYSE: MNK) to $87.00 (from $89.00) but maintained a Buy rating after updating thier model ahead of the 3Q:16 Earnings call on Nov 29.
Koffler commented, "We model $855.5M in 3Q:16 revenues and EPS of $1.92 vs. $834.2M and $1.91 consensus. Our model has been updated for the divested nuclear imaging business as well as a conservative market withdrawal of methylphenidate ER in 2Q:17. We also lowered estimates for the specialty generics business in 2016-2017 since mgmt. continues to reiterate its cautious stance and expects the business to remain under pressure next year. The stock has sold off on what we view as inflammatory short-seller comments on Acthar, rather than on any weakness in fundamentals. Consensus estimates appear beatable heading into the Nov 29 print and we think buy-backs were likely this quarter- so we reiterate our Buy rating but trim PT to $87 from $89 on model updates."
Notes Acthar scares continue to plague the stock: "Because of the unusual regulatory history of the drug and its high price, Acthar remains an easy target for far-fetched arguments. While the drug has more government utilization than we previously expected (~50%), usage has been appropriately restricted to patients who do not respond to steroids. Historically, drugs have only been removed from Part D formularies for safety or efficacy issues, so we believe it is unrealistic to expect Part D plans to suddenly stop reimbursing the product. Plus Acthar is already in the most restrictive reimbursement tiers within government plans, so further restrictions appear unlikely. Mallinckrodt is now conducting a number of placebo-controlled trials in patients already receiving steroids to highlight Acthar's efficacy and economic benefits when used appropriately. We model 3Q:16 Acthar revs of $304.3M vs consensus $309.3M Bloomberg consensus."
Shares of Mallinckrodt plc closed at $56.00 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Goldman Sachs Downgrades Marvell (MRVL) to Sell
- Evercore ISI Raises Price Target on Regions Financial (RF) to $15 After Meeting with Management
- KLR Group Raises Price Target on PDC Energy (PDCE) to $90
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, Analyst PT Change
Related EntitiesEarnings, Irina Koffler
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!